Browse by Journal Title

Article

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky, F., Middeke, J.M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S.J., Kim, T.M., Ottmann, O., Chromik, J., Quinson, A.M., von Wangenheim, U., Burkard, U., Berk, A. and Schmitz, N.
Investigational New Drugs 38 (5): 1472-1482. October 2020

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
Abolhassani, M., Guais, A., Sanders, E., Campion, F., Fichtner, I., Bonte, J., Baronzio, G., Fiorentini, G., Israel, M. and Schwartz, L.
Investigational New Drugs 30 (4): 1331-1342. August 2012

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
Kratz, F., Fichtner, I. and Graeser, R.
Investigational New Drugs 30 (4): 1743-1749. August 2012

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Bergman, A.M., Adema, A.D., Balzarini, J., Bruheim, S., Fichtner, I., Noordhuis, P., Fodstad, O., Myhren, F., Sandvold, M.L., Hendriks, H.R. and Peters, G.J.
Investigational New Drugs 29 (3): 456-466. June 2011

Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.
Bijnsdorp, I.V., Schwendener, R.A., Schott, H., Fichtner, I., Smid, K., Laan, A.C., Schott, S., Losekoot, N., Honeywell, R.J. and Peters, G.J.
Investigational New Drugs 29 (2): 248-257. April 2011

INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Graeser, R., Esser, N., Unger, H., Fichtner, I., Zhu, A., Unger, C. and Kratz, F.
Investigational New Drugs 28 (1): 14-19. February 2010

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma.
Reichardt, P., Oechsle, K., Pink, D., Bokemeyer, C., Schneller, F., Issels, R., Kanz, L. and Hartmann, J.T.
Investigational New Drugs 21 : 481-486. 1 November 2003